Financial Report: Lilly

Lilly

1Q Revenues: $5.9 billion (+15%)

1Q Earnings: $1.5 billion (-66%)

Comments: Trulicity sales were up 40% to $1.2 billion driven by increased volume, partially offset by lower realized prices. Humalog sales were $695.8 million, down 5% driven primarily by lower realized prices due to changes in estimates for rebates and discounts and changes in segment mix, partially offset by increased volume. Alimta sales were $560.1million, up 12% primarily driven by increased volume. Talz sales were $443.5 million, up 76% driven by increased volume. Humulin sales were $315.7 million, up 6% driven by increased volume, partially offset by lower realized prices. Revenue in the U.S. increased 15%, to $3.3 billion. Key growth products, include Trulicity, Taltz, Verzenio, Emgality, Basaglar, Jardiance, and Baqsimi, as well as for Humalog, was partially offset by decreased volume for Cialis due to loss of patent exclusivity. The company estimates that U.S. volume growth in the first quarter was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased U.S. revenue by approximately $200 million.
 

CPhI China 2020 To Be Postponed to Dec. 16-18th,

Register as Visitor to the 20th Edition of CPhI China!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.